Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERA trial of adjuvant Herceptin duration in HER2-positive primary breast cancer
ISRCTN82811952Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (3 arms), sponsored by Roche. Primary endpoints: Disease-free survival, Relapse-free survival and 3 more. Started Mar 2002; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN82811952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82811952.